However, the precise impact of DAA treatment on TSP2 levels remains unknown, and there is a lack of understanding on the predictive performance of TSP2 for carcinogenesis in real‐world HCV cohorts that include patients with a history of HCC. Here, THBS2 is linked to hepatocellular carcinoma.